Detalhe da pesquisa
1.
Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes.
Brain
; 143(5): 1555-1571, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438414
2.
Atomoxetine restores the response inhibition network in Parkinson's disease.
Brain
; 139(Pt 8): 2235-48, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27343257
3.
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.
Hum Brain Mapp
; 37(3): 1026-37, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26757216
4.
18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy.
J Neurol
; 267(2): 341-349, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31641878
5.
Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features.
Alzheimers Dement (Amst)
; 11: 690-699, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31667328
6.
[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.
Neurology
; 90(22): e1989-e1996, 2018 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703774
7.
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
Neuropsychopharmacology
; 41(8): 2188, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27282105